Roughly a quarter of 38 viral samples from people treated with Xofluza had mutations in their genomes that made the pathogens less susceptible to the drug.

Roughly a quarter of 38 viral samples from people treated with Xofluza had mutations in their genomes that made the pathogens less susceptible to the drug.